STERIS plc

STERIS trades at a strikingly elevated 29.7x P/E relative to the orthopedic equipment sector median of ~22x, suggesting premium valuation despite sitting 15–20% below its 52-week peak. The RSI of 39.4 signals oversold territory, creating potential reversal tension against the extended multiple. Short interest remains modest at 1.88% of float, implying limited squeeze catalysts. The valuation premium paired with momentum weakness raises questions about whether market confidence in STERIS's growth trajectory justifies the cost relative to peers, or if the recent pullback offers a reprieve before further compression.